Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
Madison, N.J. – Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today the end of its collaboration agreements with Solvay Pharmaceuticals for the development and commercialization of bifeprunox as well as other compounds in earlier stages of development for the potential treatment of schizophrenia and other psychiatric conditions.
Wyeth terminated the collaboration with Solvay after assessing the opportunity for bifeprunox and determining it would not have sufficient commercial value for the two companies to share.
All development and commercialization rights in North America for bifeprunox, an investigational atypical antipsychotic, as well as global rights for the other compounds will now revert to Solvay Pharmaceuticals.
About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.